BENDEKA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy relative to first-line therapies other than chlorambucil has not been established.

Scroll down
Scroll up

 

You are about to leave this site

You are about to leave BENDEKAHCP.com and enter a website operated by a third party.

Would you like to continue:

 

Are you a healthcare professional?

The information on this site is intended for healthcare professsionals in the United States. Are you a healthcare professional in the United States?

 

Contact us

Medical Information

For healthcare professionals or patients with specific medical questions about BENDEKA®, please contact:

Teva Medical Information

1-888-4-TEVARX (1-888-483-8279)

To request more information about BENDEKA, click here.